arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Entera Bio Ltd.

ENTX

$2.87 ▲ +0.04 (+1.23%) at close

10 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Entera Bio Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $132.6M

Dividend Yield —

Revenue Growth -76.8%

Op. Margin —

ROIC -88.0% ↗

FCF / Share $-0.16 ↗

Trailing P/E 11.5x

Price / Book 10.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$42.00K

↓ -76.8% —

Net Income Profit after all expenses

$-11.44M

↓ -19.9% —

FCF / Share Free cash flow per share

$-0.16

↑ +10.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 7 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Revenue Growth YoY (%)	-76.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1060%)	—	N/M	-76.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1057%)	56.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+605%)	—	—	—	—	—
EPS Growth YoY (%)	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-19.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-31.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-4.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-19.9% Weak ↓ Weak Declining Year-over-year change in net income	-7.3% Weak ↓ Weak Declining Year-over-year change in net income	32.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-7.3% Weak ↓ Weak Declining Year-over-year change in net income	-8.7% Weak ↓ Weak Declining Year-over-year change in net income	-3.9% Weak ↑ Weak Improving Year-over-year change in net income	-4.8% Weak ↑ Weak Improving Year-over-year change in net income	8.0% Fair Fair Year-over-year change in net income	-833.9% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	10.7% Fair ↓ Fair Declining Year-over-year change in free cash flow	28.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	42.0% Excellent Excellent Year-over-year change in free cash flow	-25.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-32.1% Weak Weak Compound annual revenue growth over 3 years	-31.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	-35.1% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—
EPS CAGR 3Y (%)	-17.8% Weak Weak Compound annual EPS growth over 3 years	-19.0% Weak Weak Compound annual EPS growth over 3 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF / Net Income (x)	0.65x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Return on Invested Capital (%)	-88.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-118.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-85.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-111.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-149.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-72.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-102.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-75.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-99.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-114.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-87.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-682%)	-118.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-887%)	-85.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-671%)	-111.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-841%)	-54.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-460%)	-149.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1096%)	—	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Net Debt (USD)	$-7.11M	$-8.66M	$-11.02M	$-12.31M	$-24.89M	$-8.59M	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.02	—	—	—	—	—
Basic EPS, GAAP (USD)	$0.25	$0.25	$0.31	$0.45	$0.47	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.16	$-0.18	$-0.25	$-0.44	$-0.35	—	—	—	—	—
Book Value per Share (USD)	$0.28	$0.21	$0.29	$0.41	$0.78	$0.36	—	—	—	—
Tangible Book Value per Share (USD)	$0.28	$0.21	$0.29	$0.41	$0.78	$0.36	—	—	—	—
Basic Weighted Avg Shares (shares)	46.19M	37.65M	29.01M	28.81M	26.13M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Working Capital (USD)	$13.10M	$7.80M	$10.17M	$11.51M	$22.17M	$7.27M	—	—	—	—
Total Equity (USD)	$13.10M	$8.08M	$10.39M	$11.75M	$22.57M	$7.51M	—	—	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Sales/Revenue/Turnover (USD)	$42.00K	$181.00K	$0.00	$134.00K	$571.00K	$365.00K	—	—	—	—
Depreciation Expense (USD)	$30.00K	$46.00K	$56.00K	$64.00K	$53.00K	$63.00K	—	—	—	—
Net Income, GAAP (USD)	$-11.44M	$-9.54M	$-8.89M	$-13.07M	$-12.19M	$-11.22M	$-10.79M	$-10.30M	$-11.20M	$-1.20M
Operating Cash Flow (USD)	$-7.37M	$-6.82M	$-7.31M	$-12.50M	$-9.06M	$-10.56M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 25 quarters

Entera Bio Ltd.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ENTX with peers